Registration number:
Bioscience IP Limited
for the Year Ended 31 March 2026
Bioscience IP Limited
Contents
|
Company Information |
|
|
Balance Sheet |
|
|
Notes to the Unaudited Financial Statements |
Bioscience IP Limited
Company Information
|
Director |
Mr P C Banford |
|
Registered office |
|
|
Accountants |
|
Bioscience IP Limited
(Registration number: 07199879)
Balance Sheet as at 31 March 2026
|
Note |
2026 |
2025 |
|
|
Fixed assets |
|||
|
Tangible assets |
|
|
|
|
Current assets |
|||
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Provisions for liabilities |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Retained earnings |
|
|
|
|
Shareholders' funds |
|
|
For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
|
• |
|
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
|
......................................... |
Bioscience IP Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
General information |
Bioscience IP Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
These financial statements were authorised for issue by the
|
Accounting policies |
Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Turnover
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and
Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or
directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Bioscience IP Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Fixtures & Fittings |
15 % Reducing Balance Method |
|
Computer Equipments |
33% Streight Line Method |
Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
|
Staff numbers |
The average number of persons employed by the company (including the director) during the year, was
Bioscience IP Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
Tangible fixed assets |
|
Plant and machinery |
Total |
|
|
Cost or valuation |
||
|
At 1 April 2025 |
|
|
|
Additions |
|
|
|
Disposals |
( |
( |
|
At 31 March 2026 |
|
|
|
Depreciation |
||
|
At 1 April 2025 |
|
|
|
Charge for the year |
|
|
|
Eliminated on disposal |
( |
( |
|
At 31 March 2026 |
|
|
|
Carrying amount |
||
|
At 31 March 2026 |
|
|
|
At 31 March 2025 |
|
|
|
Debtors: amounts falling due within one year |
|
2026 |
2025 |
|
|
Trade debtors |
|
|
|
Other debtors |
|
|
|
|
|
|
Creditors |
Creditors: amounts falling due within one year
|
2026 |
2025 |
|
|
Due within one year |
||
|
Trade creditors |
- |
|
|
Taxation and social security |
|
|
|
Other creditors |
|
|
|
|
|